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Abstract   
Glioblastoma multiforme (GBM) are intracranial tumors of the central nervous system and 
the most lethal amongst solid tumors. Current therapy is palliative and is limited to surgical 
resection followed by radiation therapy and temozolomide treatment. Aberrant WNT 
pathway activation mediates not only cancer cell proliferation but promotes radiation and 
chemotherapeutic resistance. WNT antagonists such as the secreted frizzled-related protein 
(sFRP) family have an ability to sensitize glioma cells to chemotherapeutics, decrease 
proliferation rate, and induce apoptosis. During tumor development, sFRP genes (1 to 5) are 
frequently hypermethylated, causing transcriptional silencing. We investigated a possible 
involvement of methylation-mediated silencing of the sFRP gene family in human GBM 
using four human glioblastoma cell lines (U87, U138, A172, and LN18). To induce 
demethylation of the DNA, we inhibited DNA methyltransferases through treatment with 5-
Azacytidine. Genomic DNA, RNA, and total protein were isolated from GBM cells before 
and after treatment. We utilized bisulfite modification of genomic DNA to examine the 
methylation status of the respective sFRP promoter regions. Pharmacological demethylation 
of the GBM cell lines demonstrated a loss of methylation in sFRP promoter regions, as well 
as an increase in sFRP gene-specific mRNA abundance. Western Blot analysis demonstrated 
an increased protein expression of sFRP-4 and increased levels of phosphorylated-β-catenin. 
These data indicate an important role of methylation-induced gene silencing of the sFRP gene 
family in human GBM. 






Glioblastoma multiforme (GBM) are the most aggressive amongst solid tumors within the 
central nervous system, arising from glia cells or their precursors1. Current therapeutic 
approaches are limited to surgical resection followed by radiation therapy and temozolomide 
treatment2. However, these therapies have little effect on the recurrence rate of these highly 
invasive brain tumors and their associated poor prognosis. Patients’ median survival rate post 
diagnosis is generally less than one year3. Tumors are characterized through the presence of 
neoplastic cells, which differ from normal tissue in respect to their proliferation pattern, 
morphology, and gene expression4.  
The WNT pathway plays a key role in cell proliferation and consists of highly conserved 
WNT protein ligands that bind to the frizzled (Fz) receptors. Activation triggers a signal 
transduction cascade in which glycogen synthase kinase3 (GSK3) and β-catenin are 
important downstream mediators5,6. 
In the absence of WNT signaling, GSK3 phosphorylates cytoplasmic β-catenin, making it a 
target for degradation by the proteasome7. However, during aberrant WNT-pathway signaling 
activation, GSK3 is inactivated, resulting in increased levels of unphosphorylated 
cytoplasmic β-catenin. This accumulation of cytoplasmic β-catenin increases its translocation 
to the nucleus where it activates a variety of target genes involved in tumor development and 
progression8. Therefore, a finely tuned homeostatic balance between the cytoplasmic and 
nuclear β-catenin determines the final outcome of the WNT signaling pathway. Such balance 
is brought about through extracellular WNT antagonists such as the secreted frizzled related 
protein (sFRP) family, which possesses a domain similar to one in the Fz receptor protein(s)9. 
By binding to the Fz receptor, the accumulation of free -β-catenin can act as an antagonist, 
which in turn, counteracts WNT signaling. The sFRP family has shown an ability to sensitize 
glioma cells to chemotherapeutics, decrease their proliferation rate, and induce apoptosis10. It 
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has been shown in various tumors, particularly during tumor development, that these genes 
are frequently hypermethylated, and thereby inducing transcriptional silencing11. 
Downregulation and gene silencing of the sFRP family through epigenetic modifications 
have been demonstrated in colorectal and prostate cancers12. DNA methylation has emerged 
as an additional and important mechanism in the process of epigenetic gene silencing13. The 
objective of this study was to investigate and examine the involvement of methylation-
mediated silencing of the sFRP gene family in human GBM, using four different GBM cell 
lines. In order to induce demethylation of the DNA, we inhibited DNA methyltransferases 
through treatment with 5-Azacytidine (5-Aza), a cytidine analogue that incorporates into the 
chemical structure of DNA and RNA. 
 
Materials and Methods 
Cell culture 
A total of four human glioblastoma (GBM) cell lines (U87, U138, A172, and LN18) were 
obtained from American Type Culture Collection (Manassas, USA). U87 and LN18 are able 
to form solid tumors after inoculation in nude mice, whereas U138 and A172 show no 
tumorigenicity (www.atcc.org). U87, U138, and A172 cells were cultured in DMEM-F12 
medium supplemented with 10% fetal bovine serum (HyClone, Logan, USA) and 1% 
penicillin streptomycin sulfate (HyClone, Logan, USA) at 5% CO2, 37˚C, and 95% humidity. 
LN18 Cells were cultured in DMEM-F12 medium containing 5% fetal bovine serum and 1% 
penicillin streptomycin sulfate at 5% CO2, 37˚C, and 95% humidity. To analyze the effects of 





5-Azacytidine (5-Aza) was purchased from Sigma-Aldrich (St. Louis, USA). After 
establishing a dose response effect based on results from a MTT Viability assay, cells were 
incubated with 20µM 5-Aza for 72h after a 24 h seeding period since this dose and treatment 
time provided consistent reduction in cell viability across all cell lines. Media containing the 
drug were changed every day. 
 
Viability Assay 
GBM cells were seeded into 96-well plates at a density of 2×104 per well (100 µl). Wells 
with drug-free medium were used as negative control. The cells were treated for 24h, 48h, or 
72h. At 4h before the desired time points, 10 µl of MTT solution (5 mg/ml) was added into 
each well and cells were incubated at 5% CO2, 37˚C, and 95% humidity for another 4h. The 
medium was removed and 100 µl of DMSO were added into each well. The absorbance was 
detected at 570 nm with a Microplate Reader. 
 
DNA Isolation 
Genomic DNA was extracted from all cell lines using a GeneJET Genomic DNA Purification 
Kit (Fermentas, Thermo Fisher Scientific Inc., Canada) according to the manufacturer's 
instructions. DNA integrity and quality were evaluated by spectrophotometric analysis. 
 
RNA extraction and reverse transcription 
Total RNA was extracted from human GBM cells using TRIzol reagent (Invitrogen) in 
accordance with the manufacturer's instructions. The RNA pellet was dissolved in 50 µL of 
DEPC treated water. RNA integrity and quality were evaluated through both gel 
electrophoresis and spectrophotometric analysis. 
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The RNA was reverse transcribed using iScript cDNA Synthesis Kit (Bio-Rad) according to 
the manufacturer's instructions, using 1µg of total RNA as input material. 
 
PCR 
PCR reactions were employed using 10µl of 2x PCR Master Mix (Thermo Fisher Scientific, 
USA), 0.5µM of each forward and reverse primer, 1µl of template cDNA, and water adjusted 
to 20µl. PCR products were analyzed by agarose gel electrophoresis. Primers14 used for PCR 
amplification of this cDNA are given in Table 1. 
Table 1 qPCR Primer Sequences and annealing temperatures 
Methylation-specific PCR 
The methylation status of all 5 sFRP genes in human GBM cell lines was determined by 
methylation specific polymerase chain reaction (MSP). Briefly, 1 μg of genomic DNA was 
bisulfite-treated with the EpiTect Bisulfite Kit (Qiagen, Hilden, Germany). Bisulfite-treated 
DNA was amplified using 10µl of 2x PCR Master Mix (Thermo Fisher Scientific, USA), 
0.5µM of each forward and reverse primer, 1µl of template DNA, and water adjusted to a 
final volume of 20µl. PCR products were analyzed by agarose gel electrophoresis. Previously 
described primers specific for either methylated or unmethylated DNA12 are shown in Table 
2. 
Table 2 MSP Primer Sequences and annealing temperatures 
 
Real-time PCR  
Quantitative real-time (qPCR) was performed using an AB ViiA 7 real-time PCR system 
(Applied Biosystems, Foster City, CA) and KAPA qPCR SYBR green PCR Master Mix 
(Geneworks, Australia). Reaction mixtures consisted of 5 μl of 2× KAPA SYBR green 
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Master Mix, 0.5 μM of each forward and reverse primer, 1 μl of template, 0.2µM ROX low, 
and water adjusted to 10 μl. Each reaction mixture was loaded into 96-well PCR plates and 




Protein was extracted from cells using radioimmunoprecipitation (RIPA) buffer. Protein 
Detection and Quantitation was estimated using the Direct Detect® Spectrometer (Millipore, 
Temecula, CA). Electrophoretic separation of proteins was performed by discontinuous 
(Laemmli) SDS-PAGE using the Mini-PROTEAN® II electrophoresis cell (Bio-Rad). 
Thereafter, proteins were transferred onto nitrocellulose membranes using the iBlot gel 
transfer device (Invitrogen). Membranes were then incubated for 1h in blocking solution (20 
mM Tris pH 7.6, 140 mM NaCl, 0.1% Tween-20, 5% w/v non-fat dry milk) and then washed 
three times for 5 min with Tris-buffered saline containing Tween-20 (TBS-T: 20 mM Tris pH 
7.6, 140 mM NaCl, 0.01% Tween-20). Primary antibodies (sFRP-4, ß-Actin, phosphorylated-
ß-catenin, and total ß-catenin) were diluted 1:1000 with PBS-T containing 5% w/v BSA, and 
the membranes were incubated overnight at 4°C with gentle agitation. Secondary antibodies 
(Anti-Rabbit-IgG) were diluted 1:2000 with PBS-T containing 5% w/v BSA, and the 
membranes were incubated for 1h at 4°C with gentle agitation. 
 
Statistics                                                                                                                          
Statistical analysis was performed with GraphPad Prism V5.01 (GraphPad Software, La Jolla, 
USA) using a two-tailed Student's t-test showing significance with P<0.05 as *; P<0.01 as **; 





Effect of 5-Aza on GBM cells 
Tumor cell viability was determined in the presence of increasing drug (5-Aza) 
concentrations using a total of 4 GBM cell lines. The 5-Aza concentrations ranged from 0µM 
in the untreated control to 30µM, while the incubation period was 24h, 48h, and 72h (Figure 
1) Viability of the treated cells is reported relative to their untreated control.  
Figure 1 MTT dose response results for 4 GBM cell lines (U87, U138, LN18, and A172) 
treated with increasing concentrations of 5-Azacytidine for 24h, 48h, and 72h (*= p< 0.05, 
**= p<0.01, ***= p< 0.001). 
There was no significant decrease in cell viability in U87 after 24h treatment with any 
concentration of 5-Aza. However, viability decreased significantly to about 50% after 48h of 
treatment, even in samples treated with the lowest dose. After incubation for 72h, only the 
cells treated with 30µM 5-Aza showed an additional decrease in viability to less than 50%.  
The treatment of U138 cells with 5-Aza had no significant effect on the viability of the cells 
after 24h incubation. Measurements after 48h of treatment indicated a response to rising 
concentrations of the drug. A reduction in viability of about 20% compared to the control was 
measured in the cells treated with 30µM 5-Aza for 48h. U138 showed a similar response to 
U87 after the 72h treatment period. Cell viability decreased >50% in samples treated with 
20µM and 30µM 5-Aza.  
In LN18 cells, no significant change in viability was measured after 24h and 48h treatment, 
apart from samples that were treated with 30µM for 48h. 72h after incubation, more 




Cell line A172 showed a similar pattern in every treatment group. Viability decreased more 
in cells treated with higher concentrations of the drug. However, no IC50 value was achieved, 
even after 72h of treatment with 30µM of 5-Aza.  
 
Methylation analysis of the sFRP promoters in human GBM 
The chosen 5-Aza treatment (20µM for 72h) was performed on the four GBM cell lines to 
introduce demethylation into their genomic DNA. Isolated DNA was then bisulfite treated for 
use in the MSP experiments. MSP is a sensitive technique designed to investigate changes in 
DNA methylation of CpG dinucleotides within promoter regions, so called CpG islands. We 
used MSP to detect methylation patterns in promoters of the five human sFRP genes in 
human GBM cells to distinguish between methylated and unmethylated DNA. Methylation 
analysis was performed pre- and post-treatment with 5-Aza. Figure 2 shows the results of the 
MSP performed on DNA of all cell lines and for all genes investigated.  
Figure 2 MSP results for sFRP-1,2,3,4, and 5 analyzed in U87, U138, LN18, and A172 cells.  
All four GBM cell lines showed a hypermethylated (M) promoter region of all sFRPs in the 
untreated cells. However, following treatment, all cell lines lacked promoter methylation in 
the analyzed region, as indicated by exclusive amplification with primers specific for the 
unmethylated DNA sequence. 
 
In vitro demethylation of the sFRP promoters 
To prove a direct association of sFRP promoter demethylation with an increased sFRP-
specific mRNA expression, we treated all four GBM cell lines with 20µM of 5-Aza. We 
determined sFRP promoter methylation and sFRP expression before and after the drug 
treatment. mRNA analyses after drug treatment (Figure 3) confirmed that sFRP promoter 
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demethylation had occurred in all of the originally methylated cell lines by the presence of 
signals indicating an unmethylated sFRP promoter. Those cell lines gaining unmethylated 
promoter sequence after treatment consistently showed elevated sFRP mRNA expression.  
 
Figure 3 Real-time qPCR results for sFRP-1,2,3,4,5 and ABCG2 analyzed in U87, U138, 
LN18, and A172 cells.  
sFRP-1 mRNA induction, as determined by real-time PCR, was up to 15-fold (U87) 
compared to originally methylated cells. However, sFRP-1 mRNA expression in A172 did 
not undergo significant changes (Figure 3, sFRP-1, D). 
Figure 3 compares sFRP-2 mRNA expression between untreated and 5-Aza treated samples, 
demonstrating a significant upregulation in samples with a demethylated promoter region. 
The fold change of sFRP-2 upregulation with respect to the matching control was up to 3-fold 
as shown in U138 (Figure 3, sFRP-2, B). A distinct increase of sFRP-2 mRNA expression 
could be observed in 2 of the 4 cell lines, with no change in LN18 and no detectable 
expression in A172 cells.  
Demethylation of its promoter had a functional effect on expression of sFRP-3 specific 
mRNA. Upon treatment with 5-Aza, expression of sFRP-3 mRNA increased up to 3-fold 
(Figure 3, sFRP-3, A) in all cell lines but LN18, where the expression levels were not 
significantly different to its untreated control.  
The sFRP-4 mRNA expression levels were significantly elevated in all cell lines and ranged 
from 1.6-fold (Figure 3, sFRP-4, C) to 3.5-fold (Figure 3, sFRP-4, B). 
Results for the sFRP-5 expression demonstrate a rise in mRNA levels of up to 5-fold 
throughout the four cell lines post-treatment with 5-Aza. 
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To include a positive control to the mRNA analysis, we investigated the expression levels of 
the ABCG2 drug transporter, where 5-Aza treatment has been shown to lead to increased 
mRNA expression in renal carcinoma15.  
 
Western blotting                                                                                                                   After 
investigating the methylation patterns of the sFRP promoter regions pre- and post-treatment 
with the DNA demethylating drug 5-Aza, showing a loss of methylation in all genes and 
increased mRNA expression after treatment, we addressed the effect on the protein 
expression. 
Figure 4 Western Blot results for sFRP-4, phosphorylated-β-catenin, total β-catenin, and β-
actin analyzed in U87, U138, LN18, and A172 cells.  
Figure 4 shows the results of Western blotting using rabbit anti-human sFRP-4, 
phosphorylated-β-catenin, total β-catenin, and β-actin polyclonal antibodies.  
sFRP-4 protein expression increased up to 2.3-fold in A172 cells after treatment. 
Phosphorylated β-catenin protein levels showed a significant elevation of up to 50% 
compared to the control, while the amount of total-β-catenin and β-actin remained unaltered 
by the treatment with 5-Aza. 
Discussion 
Tumor cells commonly alter their protein expression profile in response to increased or 
decreased modifications in the methylation status of specific genes16. Changes in DNA 
methylation have been proposed to play an important role in the aberrant expression of tumor 
cell genes17. Experimental data obtained using cultured cells that were treated with 5-
Azacytidine, which causes a stable and conserved DNA hypomethylation18 and activation of 
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enzyme genes such as O6-methylguanine-DNA methyltransferase (MGMT), substantiate this 
hypothesis.  
MGMT is a DNA repair enzyme that removes mutagenic and cytotoxic adducts from the O6 
position of guanine, but it is usually downregulated during tumorigenesis19. In tumor tissue, 
activation of the MGMT pathway through demethylation of its promoter has been shown to 
induce cell death20. 
Altered gene expression due to epigenetic silencing processes such as DNA methylation of 
their gene promoter, has been previously reported21. Typically, the altered genes include 
those involved in important pathways such as proliferation, apoptosis, and WNT signalling22. 
The WNT pathway is essential in many biological processes such as proliferation, 
differentiation, migration and survival of cells23–26 but its aberrant activation plays a key role 
in tumorigenesis8.  
Several new pathway contributors have been discovered over recent years and a conclusion 
has been formed that the involvement of canonical WNT signaling in the manifestation of 
cancer is most likely due to inappropriate gene activation mediated through β-catenin27. 
Canonical WNT signaling can be inhibited by a variety of antagonists, such as the sFRP gene 
family, which is often regulated and silenced due to promoter hypermethylation in human 
carcinogenesis12,28,29. Of the 5 currently known sFRP isoforms, sFRP-1 and sFRP-2 have 
been identified as targets of epigenetic inactivation in human brain cancers such as astrocytic 
gliomas to date30, and we asked whether additional members of the sFRP family might be 
affected by epigenetic silencing in human glioblastoma multiforme. 
Hypermethylation of sFRP-1, sFRP-2, sFRP-3, sFRP-4, and sFRP-5 was detected in all four 
GBM cell lines (U87, U138, LN18, A172) examined before pharmacological demethylation 
of their genomic DNA through incubation with 20µM 5-Azacytidine for 72h. Reports on the 
involvement of hypermethylation in regulation of the sFRP gene family have been previously 
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reported dealing with mesothelioma, colorectal cancer, and gastric cancer12,28,31,32 and 
substantiate our findings in GBM. sFRP-1 protein expression was studied in renal cell 
carcinoma33. sFRP-1 promoters were shown to be hypermethylated in renal cell carcinoma 
specimens and showed a significant downregulation of their mRNA levels compared to 
normal kidney tissue. Hypermethylation of the promoter regions correlated with almost 
complete loss of sFRP-1 at the protein level, indicating involvement of methylation mediated 
silencing33 and substantiates our findings. 
Re-expression of sFRP-2 in mammary cells has been shown to substantially inhibit 
proliferation rates after treatment34. This was assessed through detection of the growth 
promoting gene cyclin D1, which is a direct indicator for active Wnt signaling35.  Promoter 
hypermethylation of sFRP-2 has been previously shown in human gastric cancer32, which 
agrees with our findings in all GBM cell lines pre-treatment. 
However, the involvement of DNA methylation seems unclear in studies focusing on sFRP-3. 
Suzuki et al.12 claim that the sFRP-3 promoter does not possess CpG-Islands in its promoter 
and is therefore not affected by DNA methylation, and processes involved with 
downregulation of this gene are still unclear.  
However, others detected methylation-dependent downregulation of sFRP-3 mRNA in a 
methylation analysis of renal cell carcinoma36 and melanoma37. Furthermore, Lin et al. have 
detected methylation of sFRP-3 in hepatocellular carcinoma38 and Marsit et al. described 
increased methylation of the sFRP-3 promoter in bladder cancer29. These previous reports 
substantiate our findings on methylated sFRP-3 promoter sequences and, therefore, we 
suggest that gene methylation is a major reason for the down-regulation of sFRP-3 in human 
GBM. 
Moreover, we showed a loss of methylation within promoter regions after treatment and 
bisulfite conversion, using methylation specific PCR and primers specific for unmethylated 
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promoter regions of each sFRP gene. Therefore, our results suggest that epigenetic processes 
mediated through methylation of 5′-CpG-islands in the promoters of the sFRP gene family 
are involved and may be a common alteration in human glioblastoma multiforme cell lines. 
In addition, the investigations of sFRP-specific mRNA abundance before and after treatment 
revealed a significant increase of sFRP-1 (3 out of 4 cell lines), sFRP-2 (2 out of 3 cell lines), 
sFRP-3 (3 out of 4 cell lines), sFRP-4 (4 out of 4 cell lines) and sFRP-5 (4 out of 4 cell lines) 
expression after DNA-demethylating treatment, demonstrating that the sFRPs are 
transcriptionally silenced by epigenetic processes in human glioblastoma multiforme. This 
has been shown by Qi et al. in colorectal tumor39, where silenced sFRP genes were associated 
with promoter hympermethylation, and reactivated sFRP mRNA expression in colorectal 
cancer through demethylating treatment. Subsequent studies further demonstrated that the 
overexpression of sFRP-1, sFRP-2, sFRP-4, and sFRP-5 downregulated WNT signaling in 
colorectal cancer cells12, where the lack of basal mRNA expression was restored by a 
treatment with demethylating 5’-aza-2'-deoxycytidine. mRNA expression after demethylating 
treatment was also studied in esophageal adenocarcinoma, which resulted in re-expressed 
sFRP mRNA in esophageal adenocarcinoma cancer cell lines40.  
Our Western blotting analysis demonstrated increased sFRP-4 and phosphorylated β-catenin 
expression after demethylating treatment. Zou et al. demonstrated that the sFRP-4 protein 
expression was downregulated in samples with hypermethylated promoter regions, while 
studies conducted in human mesothelioma cell lines state that sFRP-4 is silenced by promoter 
hypermethylation31. These studies confirm our hypothesis that methylation appears to 
functionally silence sFRP-4 gene expression in human GBM.  
In leukemia, the lack of sFRP-5 protein expression was correlated with the hypermethylation 
of its promoter. Expression could be restored using a DNA demethylating agent41. 
Restoration of the expression of sFRP-5 through demethylation, attenuated Wnt signaling in 
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ovarian cancer cells and suppressed cancer cell growth, invasion of cells, and tumorigenicity 
in mice42. 
Another group stated that treatment of the myeloid leukemia cell lines treated with 
demethylating agent 5’-aza-2'-deoxycytidine induced re-expression of previously methylated 
sFRP-1, sFRP-2, sFRP-4, and sFRP-5, and resulted in inactivation of the Wnt pathway by 
downregulating important Wnt pathway genes, and reducing nuclear localization of active, 
unphosphorylated β-catenin protein43. This corroborates well with our observations in this 
study demonstrating an increased expression of inactive phospho β-catenin protein upon 5-
Aza treatment. 
A loss of sFRP expression through epigenetic silencing may affect cell proliferation via 
activation of the WNT pathway, thereby potentially enhancing tumor growth and promoting 
malignant transformation and cancer cell survival. Demethylation of the sFRP promoter 
regions and the increased expression of their corresponding proteins may lead to inhibition of 
aberrantly activated cellular networks, thus attenuating tumorigenesis.  
In summary, our data suggest that epigenetic silencing of the sFRPs may be a key feature in 
human glioblastoma multiforme and is most likely due to hypermethylation of its promoter. 
Taking into account their ability to counter cell growth and to introduce apoptosis, the 
epigenetic status of the sFRP gene family might serve as a potent therapeutic marker for this 
highly aggressive brain tumor. 
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Figure 1. MTT dose response results for 4 GBM cell lines (U87, U138, LN18, and A172) 
treated with increasing concentrations of 5-Azacytidine for 24h, 48h, and 72h (* P = 0.05, ** 
P = 0.01, *** P = 0.001). 
Figure 2. MSP results for sFRP-1, 2, 3, and 5 analyzed in U87, U138, LN18, and A172 cells. 
M: Primer specific for methylated DNA. U: Primer specific for unmethylated DNA. Control: 
untreated cells. 5-Aza: 20µM 5-Azacytidine for 72h. 
Figure 3. Real-time qPCR results for sFRP-1,2,3,4,5 and ABCG2 analyzed in U87, U138, 
LN18, and A172 cells. White bars: Untreated controls; Grey bars: Relative mRNA expression 
of 20µM 5-Azacytidine for 72h treated cells to their untreated control (*= p< 0.05, **= 
p<0.01, ***= p< 0.001). 
Figure 4. Western Blot results for sFRP-4, phosphorylated β-catenin, total β-catenin, and β-
actin analyzed in U87, U138, LN18, and A172 cells. White bars: Untreated controls; Grey 
bars: Relative protein expression of 20µM 5-Azacytidin for 72h treated cells to their 












Table 2. qPCR Primer Sequences and annealing temperatures 
Gene Forward(5‘-3‘) Reverse(5‘-3‘) qPCR AT (°C) 
sFRP-1 atctctgtgccagcgagttt  aagtggtggctgaggttgtc 65 
sFRP-2 aggacaacgacctttgcatc ttgctcttggtctccaggat 65 
sFRP-3  aaactgtagaggggcaagca ggcagccagagctggtatag 65 
sFRP-4 cgatcggtgcaagtgtaaaa gacttgagttcgagggatgg 65 
























Table 2. MSP Primer Sequences and annealing temperatures 
Gene Specificity Forward(5‘-3‘) Reverse(5‘-3‘) AT 
(°C) 
sFRP-1 Methylated gtgtcgcgcgttcgtcgtttcgc aacgttacccgactccgcgaccg 60 
Unmethylated gagttagtgttgtgtgtttgttgttttgt cccaacattacccaactccacaacca 60 
sFRP-2 Methylated gggtcggagtttttcggagtcgcgc ccgctctcttcgctaaatacgactcg 62 
Unmethylated ttttgggttggagttttttggagttgtgt aacccactctcttcactaaatacaactca 66 
sFRP-3 Methylated ggagcgggttttttggcg gaaccccgaacacccgaaa 65 
Unmethylated ggagtgggttttttggtgtttattgt cccaaaccccaaacaccca 63 
sFRP-4 Methylated gggtgatgttatcgtttttgtatcgac cctcccctaacgtaaactcgaaacg 63 
Unmethylated gggggtgatgttattgtttttgtattgat cacctcccctaacataaactcaaaaca 60 
sFRP-5 Methylated aagatttggcgttgggcgggacgttc actccaacccgaacctcgccgtacg 65 
Unmethylated gtaagatttggtgttgggtgggatgttt aaaactccaacccaaacctcaccataca 68 
 
 
 
 
 




